Baidu
map

Lancet Oncology:Ramucirumab+紫杉醇治疗进展期胃癌疗效显著(RAINBOW Ⅲ期试验)

2014-10-24 MedSci译 MedSci原创

背景: VEGFR-2在胃癌发病机制及进展过程中发挥重要作用。Ramucirumab是一种抗VEGFR2单克隆抗体,本次研究试验目的是评价Ramucirumab联合紫杉醇对比安慰剂联合紫杉醇二线治疗进展期胃癌的疗效。 研究方法: RAINBOW研究为全球多中心随机双盲对照3期临床试验。入选标准:18岁及以上的进展期胃或胃食管结合部腺癌患者,一线氟尿嘧啶类+铂类药物治疗4个月内进展

背景:

VEGFR-2在胃癌发病机制及进展过程中发挥重要作用。Ramucirumab是一种抗VEGFR2单克隆抗体,本次研究试验目的是评价Ramucirumab联合紫杉醇对比安慰剂联合紫杉醇二线治疗进展期胃癌的疗效。

研究方法:

RAINBOW研究为全球多中心随机双盲对照3期临床试验。入选标准:18岁及以上的进展期胃或胃食管结合部腺癌患者,一线氟尿嘧啶类+铂类药物治疗4个月内进展的晚期胃癌患者;这些患者按照1:1的比例随机分配,分别静脉输注ramucirumab及安慰剂,具体用药: ramucirumab 8 mg/kg 第1,15天,紫杉醇 80 mg/m2 第1,8,15天,4周方案。

该试验应用随机置换、地理区域分层、一线治疗进展时间、病情评价等方法,主要研究终点为总生存期,意向治疗原则分析疗效, 并对接受了至少1周期试验用药的患者进行安全性分析。该试验已经完成临床试验注册,编号:NCT01170663。目前正在接受治疗的患者进入了试验推广阶段。

研究结果:


试验自2010年12月23日起至2012年9月23日止,根据随机原则,共纳入665例受试者,其中,330例患者接受Ramucirumab联合紫杉醇治疗,335例患者接受安慰剂联合紫杉醇治疗。Ramucirumab联合紫杉醇组患者的中位生存期显著高于安慰剂联合紫杉醇组(mOS 9.6m [95% CI
8.5-10.8] vs 7.4 m [95% CI 6.3-8.4], HR 0.807 [95% CI 0.678-0.962]; p=0.017)。两组3度及以上的不良反应事件发生率分别如下:中性粒细胞减少(41% vs 19%), 白细胞减少(17% vs 7%),高血压(14% vs 2%), 乏力 (12% vs 5%), 贫血 (9% vs 10%),腹痛 ( 6% vs 3%);超过5%的Ramucirumab联合紫杉醇组患者出现了3度及以上的不良反应事件。两组中3度以上中性粒细胞减少性发热事件发生率都不高(3% vs 2%)。

结论:

Ramucirumab联合紫杉醇组对比安慰剂联合紫杉醇组,患者中位生存期显著延长,可做为进展期胃癌患者新型标准二线治疗方案。


本文是MedSci原创编译整理,欢迎转载!转载请注明来源并附原文链接。谢谢!

原始出处:

Wilke H1, Muro K2, Van Cutsem E3, Oh SC4, Bodoky G5, Shimada Y6, Hironaka S7, Sugimoto N8, Lipatov O9, Kim TY10, Cunningham D11, Rougier P12, Komatsu Y13, Ajani J14, Emig M15, Carlesi R16, Ferry D17, Chandrawansa K18, Schwartz JD19, Ohtsu A20; RAINBOW Study Group.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.Lancet Oncol. 2014 Oct;15(11):1224-35. doi: 10.1016/S1470-2045(14)70420-6. Epub 2014 Sep 17.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1674339, encodeId=594416e433954, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Nov 24 21:39:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814011, encodeId=1f40181401134, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Dec 27 07:39:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663194, encodeId=fc4f1663194f3, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Tue Apr 07 16:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977411, encodeId=a46019e74110c, content=<a href='/topic/show?id=57613630b9' target=_blank style='color:#2F92EE;'>#Bow#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3630, encryptionId=57613630b9, topicName=Bow)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Dec 01 01:39:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864548, encodeId=a619186454866, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 08 07:39:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827905, encodeId=26b7182e905f3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 16:39:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911663, encodeId=1d21191166381, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 18 19:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460327, encodeId=92a1146032e0c, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Sun Oct 26 02:39:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1674339, encodeId=594416e433954, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Nov 24 21:39:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814011, encodeId=1f40181401134, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Dec 27 07:39:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663194, encodeId=fc4f1663194f3, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Tue Apr 07 16:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977411, encodeId=a46019e74110c, content=<a href='/topic/show?id=57613630b9' target=_blank style='color:#2F92EE;'>#Bow#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3630, encryptionId=57613630b9, topicName=Bow)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Dec 01 01:39:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864548, encodeId=a619186454866, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 08 07:39:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827905, encodeId=26b7182e905f3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 16:39:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911663, encodeId=1d21191166381, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 18 19:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460327, encodeId=92a1146032e0c, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Sun Oct 26 02:39:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1674339, encodeId=594416e433954, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Nov 24 21:39:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814011, encodeId=1f40181401134, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Dec 27 07:39:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663194, encodeId=fc4f1663194f3, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Tue Apr 07 16:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977411, encodeId=a46019e74110c, content=<a href='/topic/show?id=57613630b9' target=_blank style='color:#2F92EE;'>#Bow#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3630, encryptionId=57613630b9, topicName=Bow)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Dec 01 01:39:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864548, encodeId=a619186454866, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 08 07:39:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827905, encodeId=26b7182e905f3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 16:39:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911663, encodeId=1d21191166381, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 18 19:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460327, encodeId=92a1146032e0c, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Sun Oct 26 02:39:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1674339, encodeId=594416e433954, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Nov 24 21:39:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814011, encodeId=1f40181401134, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Dec 27 07:39:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663194, encodeId=fc4f1663194f3, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Tue Apr 07 16:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977411, encodeId=a46019e74110c, content=<a href='/topic/show?id=57613630b9' target=_blank style='color:#2F92EE;'>#Bow#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3630, encryptionId=57613630b9, topicName=Bow)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Dec 01 01:39:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864548, encodeId=a619186454866, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 08 07:39:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827905, encodeId=26b7182e905f3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 16:39:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911663, encodeId=1d21191166381, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 18 19:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460327, encodeId=92a1146032e0c, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Sun Oct 26 02:39:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
    2014-12-01 yuandd
  5. [GetPortalCommentsPageByObjectIdResponse(id=1674339, encodeId=594416e433954, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Nov 24 21:39:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814011, encodeId=1f40181401134, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Dec 27 07:39:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663194, encodeId=fc4f1663194f3, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Tue Apr 07 16:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977411, encodeId=a46019e74110c, content=<a href='/topic/show?id=57613630b9' target=_blank style='color:#2F92EE;'>#Bow#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3630, encryptionId=57613630b9, topicName=Bow)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Dec 01 01:39:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864548, encodeId=a619186454866, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 08 07:39:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827905, encodeId=26b7182e905f3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 16:39:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911663, encodeId=1d21191166381, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 18 19:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460327, encodeId=92a1146032e0c, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Sun Oct 26 02:39:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
    2015-06-08 minlingfeng
  6. [GetPortalCommentsPageByObjectIdResponse(id=1674339, encodeId=594416e433954, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Nov 24 21:39:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814011, encodeId=1f40181401134, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Dec 27 07:39:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663194, encodeId=fc4f1663194f3, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Tue Apr 07 16:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977411, encodeId=a46019e74110c, content=<a href='/topic/show?id=57613630b9' target=_blank style='color:#2F92EE;'>#Bow#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3630, encryptionId=57613630b9, topicName=Bow)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Dec 01 01:39:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864548, encodeId=a619186454866, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 08 07:39:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827905, encodeId=26b7182e905f3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 16:39:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911663, encodeId=1d21191166381, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 18 19:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460327, encodeId=92a1146032e0c, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Sun Oct 26 02:39:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
    2015-09-19 howi
  7. [GetPortalCommentsPageByObjectIdResponse(id=1674339, encodeId=594416e433954, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Nov 24 21:39:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814011, encodeId=1f40181401134, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Dec 27 07:39:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663194, encodeId=fc4f1663194f3, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Tue Apr 07 16:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977411, encodeId=a46019e74110c, content=<a href='/topic/show?id=57613630b9' target=_blank style='color:#2F92EE;'>#Bow#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3630, encryptionId=57613630b9, topicName=Bow)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Dec 01 01:39:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864548, encodeId=a619186454866, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 08 07:39:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827905, encodeId=26b7182e905f3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 16:39:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911663, encodeId=1d21191166381, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 18 19:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460327, encodeId=92a1146032e0c, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Sun Oct 26 02:39:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]
    2015-04-18 snf701207
  8. [GetPortalCommentsPageByObjectIdResponse(id=1674339, encodeId=594416e433954, content=<a href='/topic/show?id=e8aa13359b1' target=_blank style='color:#2F92EE;'>#Oncology#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13359, encryptionId=e8aa13359b1, topicName=Oncology)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cb7226973259, createdName=circumcision, createdTime=Mon Nov 24 21:39:00 CST 2014, time=2014-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814011, encodeId=1f40181401134, content=<a href='/topic/show?id=edff943e88a' target=_blank style='color:#2F92EE;'>#进展期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94378, encryptionId=edff943e88a, topicName=进展期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5fca128, createdName=licz0423, createdTime=Sat Dec 27 07:39:00 CST 2014, time=2014-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1663194, encodeId=fc4f1663194f3, content=<a href='/topic/show?id=769995e97d' target=_blank style='color:#2F92EE;'>#Ⅲ期试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9579, encryptionId=769995e97d, topicName=Ⅲ期试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e21b25545293, createdName=Shirley Xuan, createdTime=Tue Apr 07 16:39:00 CST 2015, time=2015-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977411, encodeId=a46019e74110c, content=<a href='/topic/show?id=57613630b9' target=_blank style='color:#2F92EE;'>#Bow#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3630, encryptionId=57613630b9, topicName=Bow)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=583c133, createdName=yuandd, createdTime=Mon Dec 01 01:39:00 CST 2014, time=2014-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864548, encodeId=a619186454866, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Mon Jun 08 07:39:00 CST 2015, time=2015-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1827905, encodeId=26b7182e905f3, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Sep 19 16:39:00 CST 2015, time=2015-09-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911663, encodeId=1d21191166381, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Apr 18 19:39:00 CST 2015, time=2015-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1460327, encodeId=92a1146032e0c, content=<a href='/topic/show?id=76eb15109f0' target=_blank style='color:#2F92EE;'>#Ramucirumab#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15109, encryptionId=76eb15109f0, topicName=Ramucirumab)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd3a6291763, createdName=liuli5081, createdTime=Sun Oct 26 02:39:00 CST 2014, time=2014-10-26, status=1, ipAttribution=)]

相关资讯

CSCO 2014:晚期胃癌腹膜转移的处理对策

        复发转移性胃癌">胃癌综合治疗论坛(2楼3号会议室)时间:9月20日09:30~10:00         报告者:复旦大学附属中山医院刘天舒 胃癌中腹膜转移约占40%~50%,胃癌腹膜转移自然病程的平均生存时

CSCO 2014:晚期胃癌姑息性放疗的是与非

        复发转移性胃癌">胃癌综合治疗论坛(2楼3号会议室)时间:9月20日10:00~10:30         报告者:中国医学科学院肿瘤医院金晶 尽管近年来胃癌的发病率呈下降趋势,但目前仍然是世界第4大恶性肿瘤,

CSCO 2014:分子时代的胃癌个体化治疗

胃癌">胃癌靶向治疗与转化性研究论坛(下)(1楼1F-1会议室)时间:9月20日16:30~16:50 报告者:天津市肿瘤医院巴一教授 胃癌是全球死亡第2位的恶性肿瘤,随着目前对于胃癌发病的基因及表观遗传学认识的不断深入,使开发一种合适的生物标志物来反映患者个体化特征从而降低胃癌死亡率成为可能。分子研究方面的最新进展为胃癌的诊断与治疗带来了新的策略。 下一代测序(NGS)是一项可以一次

CSCO 2014:青年医师论坛胃癌专场:亮点频现

连续3年,3大特色         青年医师论坛胃癌">胃癌专场策划负责人、上海交通大学医学院附属瑞金医院张俊 CSCO年会设立青年医师论坛,迄今已连续3届。这些年来,CSCO青年专家委员会(简称青委会)在CSCO指导、执行委员会的指导下,不断完善成长。 在年会上逐渐形成了形式多样、特色鲜明、契合青年医

CSCO 2014:秦叔逵阿帕替尼治疗晚期胃癌的III期研究引起轰动

甲磺酸阿帕替尼是我国产的新一代小分子抗肿瘤血管生成药物,高选择性和强效作用于VEGFR2。 阿帕替尼治疗晚期胃癌">胃癌进行了规范化系列研究,I期/IIA期研究是在复旦大学附属肿瘤医院实施的单中心试验,共纳入56例患者,获得CR为1.54%,PR为12.31%,SD为66.15%,DCR高达80%。之后,进行了随机双盲、平行对照、全国多中心的IIB期研究,主要探索阿帕尼替用于应用过紫杉

吃夜宵导致胃癌?没有证据支持

流言:总是太晚进食,会增加患胃癌的风险。吃夜宵对胃的伤害非常大,因为胃黏膜上皮细胞的寿命很短,约2~3天就要再生一次,再生过程一般是在夜间胃肠道休息时进行。经常在夜间进餐会使胃黏膜得不到及时修复,甚至破坏胃黏膜。真相:夜晚太晚进食往往被认为会“伤胃”、“使胃得不到休息”,甚至还被认为是胃癌发生的罪魁祸首。在新闻报道中,“年轻白领常年加班吃夜宵患胃癌”这样的标题也不时出现。然而,即使在一些个例中

Baidu
map
Baidu
map
Baidu
map